Lilly announces a $3 billion Dutch plant for its obesity pill

Eli Lilly said on Nov. 3 that it plans to build a $3 billion manufacturing plant in Katwijk, Netherlands, to help produce orforglipron, the company's experimental oral GLP-1 weight-loss drug, along with other oral medicines ^[1][2]. The facility, located in the Leiden Bio Science Park, will focus on cardiometabolic, neuroscience, oncology and immunology pills, and construction is expected to start next year ^[2][3].

Lilly, the world's most valuable pharmaceutical company by market value, has been investing heavily to scale up production of orforglipron even before regulators have cleared it ^[1]. The company said it expects to submit orforglipron to global regulators for obesity treatment by the end of 2025 ^[2][3]. Lilly shares rose 2.5% after the announcement ^[1].

The Dutch site is expected to create 500 skilled manufacturing jobs and about 1,500 construction jobs, and Lilly's investment depends on final government permits and local approvals ^[1][2][3]. CEO David Ricks said the Netherlands was chosen partly because of its closeness to the European Medicines Agency and its multilingual, skilled workforce ^[1]. The plant will use technologies such as paperless manufacturing, AI-driven analytics, dock-to-dock automation and spray-dried dispersion, a process that helps oral medicines absorb properly in the body ^[1][2].

This is not Lilly's only recent move to build up orforglipron manufacturing. Days earlier, the company announced a more than $1.2 billion expansion of its existing plant in Carolina, Puerto Rico, also aimed at boosting orforglipron output as part of a broader U.S. manufacturing push ^[1]. Lilly has also said it will announce two more U.S. manufacturing sites in the coming months ^[1][2]. In Europe, Lilly already has plants in France, Ireland, Italy and Spain, plus two more under construction in Ireland and Germany ^[1][2].

Why it matters for patients

Orforglipron, which Lilly is branding Foundayo, is not yet approved in the United States. Building large-scale manufacturing capacity on both sides of the Atlantic before approval suggests Lilly expects strong demand and wants to avoid the kind of shortages that have affected injectable GLP-1 drugs like Zepbound and Wegovy in past years ^[1][2]. For patients considering or waiting on an oral GLP-1 option, more manufacturing capacity built in advance could mean fewer supply disruptions if and when the drug reaches pharmacies.

The sources do not say what orforglipron might cost patients, how insurance coverage might work, or exactly when U.S. approval could come. Lilly said only that it expects to submit the drug to regulators worldwide, including likely the FDA, by the end of 2025 ^[2][3]. None of the sources given here confirm an approval date or timeline for when the pill would actually be available to patients in pharmacies.

What happens next

Construction on the Netherlands facility is expected to begin in 2026, and the investment still depends on finalizing government permits and local approvals ^[1][2][3]. Lilly has said it expects to submit orforglipron to regulatory agencies around the world for obesity treatment by the end of 2025 ^[2][3]. The company has also said it plans to announce two additional U.S. manufacturing sites in the coming months, though no locations or dates were given ^[1][2]. None of the sources specify when the FDA might decide on orforglipron or when the drug could become available to U.S. patients.